Dr. Timothy Carrothers Will Present Case Example on the Value of Modeling
and Simulation to Assess Potential for QTc Prolongation
MOUNTAIN VIEW, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Timothy Carrothers, Sc.D., senior scientist, Strategic Consulting Services, has been invited to speak to members of the pharmaceutical and biotechnology industries attending the 2nd Annual Drug Information Association (DIA) Cardiac Safety Conference, to be held in Prague, Czech Republic at the Dorint Praha Don Giovanni Hotel from December 3-4, 2007.
Dr. Carrothers will present a case study on the value of model-based
approaches to assess drug effects on QTc prolongation and develop future
clinical studies required for new drug approval. Dr. Carrothers'
presentation, "Concordance Between the Exposure-QTc Response Relationship
in the Pooled Phase 1 Data vs. Thorough QTc Study", is part of a dedicated
conference session led by pharmaceutical sponsors and regulators on
modeling the relationship between plasma concentration of a drug and its
effect on QTc prolongation as an indicator of cardiac arrhythmic risk. The
session speakers will present applied research on concentration-QTc
modeling and discuss perspectives for its contribution to decisions on the
development, regulatory approval and labeling of new drugs. A panel
discussion will also provide a forum for scientific discussion and
collaborative exchange on exposure-QTc response modeling. Additional
information can be found at http://www.d
|SOURCE Pharsight Corporation|
Copyright©2007 PR Newswire.
All rights reserved